NEWS & EVENTS
The management of Accrol Group Holdings plc (AIM:ACRL), a leading independent tissue converter, manufacturing toilet rolls, kitchen rolls, facial tissues …READ MORE
The management of Benchmark Holdings (AIM:BMK), the aquaculture biotechnology and food chain sustainability business, would like to invite you to …READ MORE
$GHT.L shares jump on excellent H1, have doubled in last year. Revs £9.9m +26%, adj EBITDA £2.2m + 46%. Clareti license sales up 100%< ...
$RBG.L better news in FY update: sales +9.2% (lfl +1.5%), 6 new bars that traded well. Results out 3 Oct, and seen in line with Board view.
$BXP.L 'delighted' to receive 4th approval from the US FDA for muscle relaxant Methocarbamol tablets. Launch in Q4, 2017, est. market $30m.
$AUG.L @Augeanplc H1 update: broadly in line, sees FY growth at low end of forecasts. Useful cost cuts, Radioactive and Industry both strong
Global markets were weak on Monday as UK / US growth expectations were cut by IMF , but UK stocks should recover a little at opening
$VAST.L conditional heads of terms for $10m external investment to drive growth plans, mostly in Romania. Would equate to 29% stake in VAST.
WHY CHOOSE ED
"MHP believes commissioned research is an important part of the toolkit to attract new investors and improve liquidity. We rate ED's analysts and research very highly as one of the leading providers in this space."
"The team at ED consistently produce high quality research and highlight profitable investment opportunities, an invaluable tool for small cap investors in this under researched space."
"Thanks for working over the weekend on this – it is really appreciated, as always Benchmark gets massive benefit from ED’s work for us, and from your team’s wise counsel at these key moments."
"There is a need now, more than ever before, for real insight and clarity to be brought to company messages for investors….I would strongly recommend Equity Development to the management of any company."
Small Cap Equity Salesman